Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of bimekizumab in moderate to severe hidradenitis suppurativa
NL-OMON54446Phase 3Recruiting
- Sponsor
- UCB
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of bimekizumab in hidradenitis suppurativa (HS) (2 arms), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Mar 2022; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON54446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54446.